OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 153 filers reported holding OCULAR THERAPEUTIX INC in Q1 2021. The put-call ratio across all filers is 0.82 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $69,303 | -39.6% | 22,071 | -0.8% | 0.00% | – |
| Q2 2023 | $114,789 | -4.8% | 22,246 | -2.7% | 0.00% | – |
| Q1 2023 | $120,530 | +74.6% | 22,871 | -6.9% | 0.00% | – |
| Q4 2022 | $69,030 | -17.8% | 24,566 | +22.2% | 0.00% | – |
| Q3 2022 | $84,000 | +1.2% | 20,095 | -2.3% | 0.00% | – |
| Q2 2022 | $83,000 | +20.3% | 20,571 | +46.6% | 0.00% | – |
| Q1 2022 | $69,000 | -24.2% | 14,035 | +7.7% | 0.00% | – |
| Q4 2021 | $91,000 | -93.8% | 13,036 | -91.1% | 0.00% | -100.0% |
| Q3 2021 | $1,458,000 | -29.2% | 145,741 | +0.4% | 0.00% | 0.0% |
| Q2 2021 | $2,059,000 | +325.4% | 145,200 | +391.7% | 0.00% | – |
| Q1 2021 | $484,000 | -22.9% | 29,529 | -2.8% | 0.00% | – |
| Q4 2020 | $628,000 | -72.3% | 30,365 | -43.8% | 0.00% | -100.0% |
| Q1 2015 | $2,268,000 | -22.2% | 54,000 | -56.5% | 0.00% | -40.0% |
| Q4 2014 | $2,916,000 | – | 124,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 5,618,861 | $116,310,000 | 100.00% |
| Opaleye Management Inc. | 6,510,000 | $134,758,000 | 17.60% |
| DELTEC ASSET MANAGEMENT LLC | 2,168,573 | $44,889,000 | 6.87% |
| Versant Venture Management, LLC | 1,465,384 | $30,333,000 | 3.15% |
| GREAT POINT PARTNERS LLC | 856,162 | $17,723,000 | 2.88% |
| Affinity Asset Advisors, LLC | 220,000 | $4,554,000 | 2.41% |
| Altium Capital Management LP | 303,174 | $6,276,000 | 2.34% |
| Endurant Capital Management LP | 290,465 | $6,013,000 | 2.17% |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 50,396 | $1,043,000 | 1.17% |
| Lisanti Capital Growth, LLC | 366,040 | $7,577,000 | 1.05% |